drugset / Trial / NCT01490788

A Comparative Bioavailability and Pharmacokinetic Study of TNX-102 2.4 mg and Cyclobenzaprine 5 mg Tablets in Healthy Adults.

NCT01490788

Phase 1 Completed 30 enrolled Tonix Pharmaceuticals, Inc.
RandomizedCrossoverOpen-labelTreatment

Summary

The trial is designed to assess the safety and tolerability of TNX-102 2.4 mg and to compare the bio-availability of TNX-102 2.4 mg and cyclobenzaprine 5 mg tablets under fasting or fed conditions.

Timeline

Start
2011-11-18
Primary completion
2011-12-30
Completion
2011-12-30

Drugs

EvaluationDrugModalityDoseRoute
Subject cyclobenzaprine Small molecule 2.4 mg
Subject cyclobenzaprine Small molecule 5 mg

Indications

No indication recorded.